Research programme: neurological disorders kinase inhibitors - Arrien Pharmaceuticals

Drug Profile

Research programme: neurological disorders kinase inhibitors - Arrien Pharmaceuticals

Alternative Names: ARN-1104; ORS 1006; ORS 1104

Latest Information Update: 12 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oros Pharmaceuticals
  • Developer Arrien Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action DYRK kinase inhibitors; LRRK2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Parkinson's disease

Highest Development Phases

  • Preclinical Parkinson's disease
  • Discontinued Alzheimer's disease; Down syndrome

Most Recent Events

  • 09 Sep 2016 Discontinued - Preclinical for Alzheimer's disease in USA (PO)
  • 09 Sep 2016 Discontinued - Preclinical for Down syndrome in USA (PO)
  • 09 Sep 2016 Preclinical development is ongoing in USA (Arrien Pharmaceuticals Pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top